Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab long-term extension study in pediatric moderate-to-severe atopic dermatitis
jRCT2031230146Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, double-blind, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants discontinued from study treatment due to adverse events. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230146.